Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to halt liver scarring in early trial

NCT ID NCT06750276

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests an experimental drug called AZD2389 in people with liver fibrosis (scarring) and compensated cirrhosis (early-stage liver damage). The goal is to check the drug's safety and how the body handles it. About 40 adults with liver disease will receive either AZD2389 or a placebo. Researchers will also look for signs that the drug affects the liver.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD2389
What this could lead to
If successful, this could point toward a new treatment to slow or stop liver scarring in people with liver disease.
What could go wrong
This is an early phase 2a trial with only 40 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

40 people

The number who actually took part.

Started

Dec 2024

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key inclusions: * Males/females aged ≥ 18 years * Indications: Presumed MASH (cohort A) or other steatotic liver disease (cohort B) with fibrosis * No significant change in weight over the last 6 months * Barrier contraceptives use by males * Capable of informed consent * Judged to be suitable for study by investigator Key exclusions: * A condition that could put the participant at risk, influence the participant's ability to participate in the trial, interfere with evaluation of the study intervention or affect the interpretation of the results * Other causes of liver disease which are not the principal inclusion criteria for each cohort * Significant elevations in liver blood tests or platelets \<140 x10\^9/L * Decompensated liver disease, hepatobiliary cancer or listing for liver transplantation * Bleeding disorders or major bleeding risk * HIV infection or hepatitis B infection * Clinically significant cardiovascular (e.g. severe ischaemic heart disease, severe heart failure or cardiac dysrhythmia) or cerebrovascular disease within the past 3 months * Stage 2 hypertension * eGFR \<60ml/min/1.73m2 * Clinically significant gastrointestinal disease which can affect the interpretation of pharmacokinetic, safety, and tolerability data * Skin disorders or ongoing wound healing * Psychiatric disorders which may negatively affect participation in the trial. * Females of childbearing potential

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic cirrhosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fibrotic liver disease metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic cirrhosis Liver fibrosis

Contacts and locations

Locations

  • Research Site

    Chandler, Arizona, 85224, United States

  • Research Site

    Rialto, California, 92377, United States

  • Research Site

    Atlanta, Georgia, 30349, United States

  • Research Site

    Morehead City, North Carolina, 28557, United States

  • Research Site

    Houston, Texas, 77079, United States

  • Research Site

    San Antonio, Texas, 78215, United States

  • Research Site

    San Antonio, Texas, 78229, United States

  • Research Site

    San Juan, 00927, Puerto Rico

  • Research Site

    Cambridge, CB2 0QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.